Measures used in the rating system before and after 2011
| Before 2011 | After 2011 |
| Reperfusion for STEMI/LBBB | Reperfusion for STEMI/LBBB |
| PCI as primary reperfusion for STEMI/LBBB (2006) Reperfusion for STEMI/LBBB within recommended time (2007–2009) | Reperfusion for STEMI/LBBB within recommended time |
| Coronary angiography in target group with NSTEMI | Coronary angiography in target group with NSTEMI |
| LMW heparin/heparin/fondaparinux during care event or PCI performed within 24 hours for NSTEMI | – |
| Aspirin or other thrombocyte inhibitor or anticoagulants at discharge following myocardial infarction | – |
| P2Y12-receptor blocker for NSTEMI | P2Y12-receptor blocker for NSTEMI |
| Beta-blocker at discharge following myocardial infarction. | – |
| Lipid-lowering drugs at discharge for myocardial infarction. | – |
| ACE-inhibitor/ARB in target group for myocardial infarction | ACE-inhibitor/ARB in target group for myocardial infarction |
| – | Share with myocardial infarction as main diagnosis (<80 years) included in RIKS-HIA |
| – | Share of myocardial infarctions <75 in RIKS-HIA undergoing follow-up (SEPHIA) |
| – | Share of smokers that had stopped smoking after 12–14 months |
| – | Share that had participated in exercise programme after 12–14 months |
| – | Share with LDL-cholesterol<2.5 mmol/L (96.7 mg/dL) after 12–14 months |
| – | Share with systolic blood pressure <140 mm Hg after 12–14 months |
ARB, angiotensin receptor blocker; LBBB, left bundle branch block; LDL, low density lipids; LMW, low molecular weight; NSTEMI, non-ST elevation myocardial infarction; PCI, percutaneous coronary intervention; RIKS-HIA, Register of Information and Knowledge about Swedish Heart Intensive care Admissions; SEPHIA, SEcondary Prevention after Heart Intensive care Admissions; STEMI, ST elevation myocardial infarction.